caa a22 4500 465789935 CHVBK 20180323112020.0 cr unu---uuuuu 170327e19901101xx s 000 0 eng 10.1007/BF00198589 doi (NATIONALLICENCE)springer-10.1007/BF00198589 Evaluation of a platinum-doxorubicin complex in experimental tumor systems [Elektronische Daten] [Franco Zunino, Graziella Pratesi, Franca Formelli, Alessandro Pasini] Summary: On the basis of previous observations indicating that the platinum (II)-doxorubicin complex (coordinated via the amino sugar) was active against resistant ascitic leukemias, the preclinical evaluation of this complex was extended to a variety of experimental tumors, including solid doxorubicin-resistant tumors (P388/DX, B16 melanoma with acquired resistance, and MXT mammary carcinoma with natural resistance). In the treatment of sensitive tumors (Gross leukemia and Lewis lung tumor) the complex provided efficacy comparable to that of doxorubicin. Among resistant models, only P388/DX, which is only weakly responsive to cisplatin itself, showed significant sensitivity to the platinum complex. Since all resistant tumors were transplanted in the same site (s.c.) of the same mouse strain, it is likely that the different tumor response reflects different underlying mechanisms of cell resistance rather than alterations in pharmacologic behavior of the anthracycline after covalent binding to platinum. The data reported in this preclinical study support the potential value of this approach to overcome selected manifestations of resistance to anthracyclines. In contrast to the highly toxic doxorubicin/cisplatin combination, doxorubicin complexation with platinum was not associated to an increase in toxicity. Kluwer Academic Publishers, 1990 doxorubicin nationallicence cisplatin nationallicence platinum-doxorubicin complex nationallicence experimental tumors nationallicence Zunino Franco Division of Experimental Oncology B, Istituto Nazionaleper lo Studio e la Cura dei Tumori, Via Venezian 1, 20133, Milano, Italy aut Pratesi Graziella Division of Experimental Oncology B, Istituto Nazionaleper lo Studio e la Cura dei Tumori, Via Venezian 1, 20133, Milano, Italy aut Formelli Franca Division of Experimental Oncology B, Istituto Nazionaleper lo Studio e la Cura dei Tumori, Via Venezian 1, 20133, Milano, Italy aut Pasini Alessandro Dipartimento di Chimica Inorganica e Metallorganica, University of Milan, Via Venezian 21, 20133, Milano, Italy aut Investigational New Drugs Kluwer Academic Publishers 8/4(1990-11-01), 341-345 0167-6997 8:4<341 1990 8 10637 https://doi.org/10.1007/BF00198589 text/html Onlinezugriff via DOI 1 research-article jats NATIONALLICENCE 856 40 https://doi.org/10.1007/BF00198589 text/html Onlinezugriff via DOI NATIONALLICENCE 700 1- Zunino Franco Division of Experimental Oncology B, Istituto Nazionaleper lo Studio e la Cura dei Tumori, Via Venezian 1, 20133, Milano, Italy aut NATIONALLICENCE 700 1- Pratesi Graziella Division of Experimental Oncology B, Istituto Nazionaleper lo Studio e la Cura dei Tumori, Via Venezian 1, 20133, Milano, Italy aut NATIONALLICENCE 700 1- Formelli Franca Division of Experimental Oncology B, Istituto Nazionaleper lo Studio e la Cura dei Tumori, Via Venezian 1, 20133, Milano, Italy aut NATIONALLICENCE 700 1- Pasini Alessandro Dipartimento di Chimica Inorganica e Metallorganica, University of Milan, Via Venezian 21, 20133, Milano, Italy aut NATIONALLICENCE 773 0- Investigational New Drugs Kluwer Academic Publishers 8/4(1990-11-01), 341-345 0167-6997 8:4<341 1990 8 10637 Metadata rights reserved Springer special CC-BY-NC licence nationallicence BK010053 XK010053 XK010000 NATIONALLICENCE NATIONALLICENCE NL-springer